Compare Ginkgo Bioworks Holdings Inc (DNA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs STMicroelectronics NV — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while STMicroelectronics NV trades at $52.06 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 63× Ginkgo Bioworks Holdings Inc's market cap, and STMicroelectronics NV pays a 0.68% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and STMicroelectronics NV for 64 Days on average.
| DNA | STM | |
|---|---|---|
Market Cap | $763.64M | $48.14B |
Volume | 3,204,177 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $15.83 | $79.91 |
52-Week Low | $5.48 | $21.20 |
Typical Hold Time | 7 Days | 64 Days |
Enterprise Value | $865.59M | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
STM trades at $52.71, down 6.18% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS beat ($0.31 vs. $0.26 expected) but missed in Q4 2025 and Q1 2026. Revenue declined from $16.1B in 2022 to $11.8B in 2025, with net income margin turning negative at -0.39% in 2026. Analyst consensus remains positive with a $77.31 price target (51.72% buy ratings), supported by strong AI data-center revenue projections exceeding $2B by 2027 (Reuters, 2026-09-09).
STM faces near-term profitability challenges but offers long-term growth potential in AI and automotive semiconductors. Key risks include execution on margin recovery and macroeconomic volatility. The stock trades at a premium P/E of 101.49, requiring sustained earnings acceleration to justify valuation. Institutional sentiment is cautiously optimistic given the 46% upside to consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
